Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelenirstat in Relapsed/Refractory AML
NCT06613217Phase 1Recruiting
- Sponsor
- Pacylex Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelenirstat in acute myeloid leukemia (AML), sponsored by Pacylex Pharmaceuticals. Primary endpoint: Recommended Phase 2 Dose at 18 months. Started Mar 2025; status: recruiting.
02
Drugs
zelenirstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06613217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613217.